tiprankstipranks
Trending News
More News >
Alnylam Pharmaceuticals (GB:0HD2)
LSE:0HD2

Compare Alnylam Pharma (0HD2) vs. Competitors

Compare
4 Followers

Comparison Results

Name
Price
Market Cap
P/E Ratio
Yearly Gain
Analyst Consensus
Analyst Price Target
Top Analysts' Price Target
Smart Score
Follow
Alnylam Pharma
$346.23
$46.18B
1,440.22
25.69%
15 Buy
3 Hold
0 Sell
Strong Buy
Incyte
$101.08
$19.86B
16.96
37.11%
7 Buy
8 Hold
1 Sell
Moderate Buy
Vertex Pharmaceuticals
$475.68
$121.25B
33.53
7.74%
20 Buy
3 Hold
0 Sell
Strong Buy
Argenx Se
$847.72
$52.36B
39.82
29.47%
16 Buy
3 Hold
0 Sell
Strong Buy
Genmab
$33.35
$20.13B
14.05
68.01%
5 Buy
2 Hold
0 Sell
Moderate Buy
BioNTech SE
$116.77
$27.93B
-44.41
-3.62%
13 Buy
2 Hold
0 Sell
Strong Buy

Performance Comparison

Ticker
Company Name
Price
Change
% Change
GB:0HD2
Alnylam Pharma
346.23
69.42
25.08%
INCY
Incyte
101.08
27.31
37.02%
VRTX
Vertex Pharmaceuticals
475.68
37.28
8.50%
ARGX
Argenx Se
847.72
182.04
27.35%
GMAB
Genmab
33.35
13.54
68.35%
BNTX
BioNTech SE
116.77
-4.11
-3.40%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts